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Abstract 
 
The study aimed to establish a function-based relationship between the physical and bulk 
properties of pre-blended mixtures of fine and coarse lactose grades with the in vitro performance 
of an adhesive active pharmaceutical ingredient (API). Different grades of micronised and milled 
lactose (Lactohale (LH) LH300, LH230, LH210 and Sorbolac 400) were pre-blended with coarse 
grades of lactose (LH100, LH206 and Respitose SV010) at concentrations of 2.5, 5, 10 and 20 
%w/w. The bulk and rheological properties and particle size distributions were characterised. The 
pre-blends were formulated with micronised budesonide and in vitro performance in a Cyclohaler 
device tested using a Next Generation Impactor (NGI) at 90 l/min. Correlations between the 
lactose properties and in vitro performance were established using linear regression and artificial 
neural network (ANN) analyses. The addition of milled and micronised lactose fines with the coarse 
lactose had a significant influence on physical and rheological properties of the bulk lactose. 
Formulations of the different pre-blends with budesonide directly influenced in vitro performance 
attributes including fine particle fraction, mass median aerodynamic diameter and pre-separator 
deposition. While linear regression suggested a number of physical and bulk properties may 
influence in vitro performance, ANN analysis suggested the critical parameters in describing in vitro 
deposition patterns were the relative concentrations of lactose fines %<4.5 µm and %<15 µm. 
These data suggest that, for an adhesive API, the proportion of fine particles below %<4.5 µm and  
and %<15 µm could be used as a critical material attributes in rational DPI formulation design.    
 
Keywords: Lactose, dry powder inhaler, quality-by-design, critical material attributes, cohesive-
adhesive balance. 
Introduction 
 
 
Carrier based dry powder inhaler (DPI) formulations are a common vehicle for the delivery of highly 
cohesive drug powders to the lungs, and use the patients’ inspiratory effort for fluidising a dose of 
powder mixture of lactose monohydrate and drug [1]. Ternary components, such as magnesium 
stearate or fine particle lactose [2], are typically added to the formulation to further optimise and 
control the detachment and deagglomeration efficiency of the drug particles from the large carrier 
particles [3].  
 
DPI drug products are an example of a complex dosage form, with many factors that influence 
drug product functionality and stability [4]. With the introduction of a quality-by-design (QbD) 
initiative by the US Food and Drug Administration (FDA), pharmaceutical companies have been 
encouraged to further understand their chemistry, manufacturing and controls (CMC) and their 
influence on product performance [5]. The current QbD paradigm focuses on the development of 
product and process design understanding to enable development of drug product that meet the 
target product profile [6]. In order to achieve this, the QbD approach warrants the development of 
mechanistic models that correlate critical material attributes (CMAs e.g. raw material 
physicochemical properties), critical process parameters (CPPs) and product functionality [6]. 
However, establishing a process and property function relationship for DPI formulation 
performance has proved to be a challenging task. This is most likely due to the lack of precise 
control of CPPs and incomplete investigation of CMAs that may directly influence the performance 
attributes of the product [7].  
 
In the case of DPIs, the excipient plays a critical role in the functionality of the drug product [8]. 
Indeed, a number of CMAs of lactose monohydrate have been identified that affect DPI drug 
product quality. For example, surface energy of the lactose measured by inverse gas 
chromatography [9], specific surface area [10], fine lactose particle content [11,12] and the energy 
required to fluidise the carrier [13]. These studies suggest, based on relatively small datasets, that 
a range of parameters adequately characterise the functional behaviour of the lactose and its 
relationship to drug product quality. However, there has been limited success in developing a 
mechanistic approach to define the CMAs of lactose monohydrate that influences drug product 
performance. 
 
Current approaches rely heavily on the use of design of experiments (DoE) and multivariate data 
analysis (MVA) to understand the relationship between drug and excipient CMAs on drug product 
performance [14]. These approaches depend on composite experimental design that is applied to 
define the design space for drug product performance for a range of formulation and process 
factors. Response variables are predicted quantitatively from the combination of these factors. 
Such approaches have been successfully utilised in the development of drug products and have 
become an integral part of pharmaceutical development risk management. With respect to DPI 
formulations, these approaches represent a systematic approach to developing theoretical 
relationships between complex factors and outputs. Podczeck recognised the need for more 
complex statistical analysis methods for understanding structure-function relationships in DPI 
formulations [15]. Zeng et al. established a two parameter model for the fine particle delivery from 
DPI formulations based on parameters describing the macroscopic shape of the carrier particles 
[16]. In both studies, multiple linear regression (MLR) was used for establishing the relationship 
between lactose properties and DPI formulation performance. The MLR approach is based on the 
assumption that the underlying relationships are linear and that the input parameters are not co-
linear. However, controlling input variables, especially in case of lactose carriers where the main 
aim during production is the control of the particle size distribution, so that co-linearity is avoided is 
difficult unless experimental design is applied [17]. These approaches do rely on multiple 
regression analysis to enable prediction of response variables on the basis of a second-order 
polynomial equation. Optimisation algorithms are then applied to define the design space. 
Prediction of pharmaceutical responses based on polynomial relationships is limited and result in 
poor estimation of drug product design space [18]. 
 
In order to overcome the shortcomings of the DoE and MVA approach, a multi-objective 
simultaneous optimisation approach incorporating artificial neural networks (ANN) are gaining 
popularity in pharmaceutical drug delivery applications. ANNs are a computational data analysis 
tool that attempt to incorporate the human brain’s capability of learning, adapting and tolerating 
faulty and noisy data to modern computers’ superior ability to perform numerical computation and 
symbol manipulation [19]. In practice, modelling data using ANNs is based on presenting the data 
to the network and training the network to recognise the underlying trends in the dataset [19]. 
Pharmaceutical examples include understanding how flow properties of excipients relate to the 
micromeritic properties of the materials [20], modelling drug dissolution [21], optimising 
formulations for controlled release tablets [22] and transdermal drug delivery products [23]. 
Hitherto, the use of artificial neural network analysis in inhalation research has been limited to 
modelling in vivo - in vitro correlations of inhalation formulations [24] and clinical effects of inhaled 
bronchodilators with the physiological parameters of individual patients [25].   
 
This study aims to further understand the function-based relationship between particle size, bulk 
property and powder rheological CMAs of lactose blends, prepared with different coarse carriers 
and milled and micronised lactose fines, and their influence on key performance attributes of an 
adhesive, micronised budesonide. Linear regression and artificial neural network (ANN) analysis 
was performed in an attempt to determine how these lactose CMAs influence DPI drug product 
performance.  
 
Materials and methods 
 
Materials 
 
Micronised budesonide was supplied and used as received from Sterling S.r.l (Perugia, Italy). 
Three different coarse lactose carriers and four different grades of commercially available fine 
particle lactose were used in the study. Two of the coarse carriers were Lactohale (LH) products, 
namely LH100 (Sieved coarse grade) and LH206 (Lightly milled coarse grade), and the third 
coarse carrier was Respitose SV010 (Sieved coarse grade), all samples were kindly donated by 
DFE Pharma (Borculo, Netherlands). Three of the different fine particle lactose fractions were also 
Lactohale grades, namely LH300 (micronised fines), LH230 (finer milled fines) and LH210 (coarser 
milled fines), also from DFE Pharma. The fourth fine particle lactose grade used was Sorbolac 400 
from Meggle (Wasserburg am Inn, Germany). 
 
Water used during the studies was Milli-Q reverse osmosis purified (Merck Millipore, Darmstadt, 
Germany) and methanol and acetonitrile were of HPLC grade and purchased from Sigma 
(Gillingham, UK). 
 
Preparation of lactose pre-blends 
 
Carrier lactose pre-blends were prepared by adding different fractions of the fine lactose samples 
to the coarse carriers at 2.5, 5, 10 and 20 %w/w concentrations, as summarised in Table I. All 
lactose pre-blends were produced in 100g batches. The fine lactose grades were sandwiched 
between the coarse carrier in either two (2.5% blends) or three layers (5, 10 and 20% blends) in a 
stainless steel cylindrical vessel with an internal diameter of 100 mm and a height of 150 mm. The 
headspace in the vessel was approximately two thirds of the volume of the container, depending 
on the fines content of the pre-blend. The mixtures were blended with a Turbula mixer (Glen 
Creston, Middlesex, UK) at 46 rpm for 60 minutes. All pre-blends were stored at 44±1% relative 
humidity (RH) and 20±2°C for at least 7 days before any further work was carried out. 
 
Particle size measurements 
 
The particle sizing of the raw materials and pre-blends was conducted using a HELOS laser 
diffraction unit in conjunction with Windox 5 software, both from Sympatec GmbH (Clausthal-
Zellerfield, Germany). The high resolution Fraunhofer model (HRLD) provided by the Windox 
software was used for calculating the particle size distributions of all the materials from the raw 
scattering data. 
 
The particle size of lactose raw materials and pre-blends were measured using a validated 
methodology, utilising the R4 lens and the RODOS dry powder disperser in conjunction with the 
Vibri dry powder feeder. The feed rate was adjusted such that an optical concentration of between 
0.5% and 5% was achieved. No data was recorded until a threshold value of 0.5% for optical 
concentration was exceeded. A dispersion pressure of 2 bar was used for measuring the lactose 
samples. The background scattering was recorded for ten seconds with the vacuum on and five 
repeated measurements of two seconds duration were recorded for the lactose samples. 
 
The PSD of micronised budesonide was characterised using a R3 lens and a Cuvette wet 
dispersion system. An aliquot of the material was dispersed in cyclohexane that contained 0.1% 
lecithin to aid the dispersion. The stirring speed was set to 1500 rpm. Prior to PSD measurements, 
the background scattering was recorded for a period of 10 seconds. To achieve a measure of the 
primary particle size, the suspension was ultrasonicated at 50% intensity of the maximum with the 
internal probe of the disperser system for one minute. After ultrasonication, the final optical 
concentration was between 3 and 10%. Five repeated measurements of five seconds were 
recorded for the drug.  
  
Cohesive-adhesive balance (CAB) measurements of budesonide 
 
A random selection of particles from the micronised batch of budesonide were attached onto 
standard V-shaped tipless cantilevers with pre-defined spring constants (DNP-020, DI, CA, USA) 
using an epoxy resin glue (Araldite, Cambridge, UK), using a previously described method [26]. A 
minimum of five probes were prepared and all colloid probes were examined with an optical 
microscope (magnification 50x) to ensure the integrity of the attached particle, before and after 
colloid probe force measurements. 
 
The crystal face of a primary crystallised sample of budesonide was used for atomic force 
microscopy-cohesive adhesive balance (AFM-CAB) measurements as described previously [26]. 
To measure the force of adhesion (drug-excipient) a smooth surface of lactose was also 
crystallised, as described elsewhere [26]. The surface roughness as measured by the Ra and Rq of 
the surfaces of crystal particles of budesonide and lactose were <1 nm and therefore suitable for 
CAB measurements. 
    
Substrates were loaded on to the AFM scanner stage, which was enclosed in a custom-built 
environmental chamber, in which the ambient conditions were maintained at a constant 
temperature of 25 ± 1.5°C and relative humidity of 35 ± 3%. The interactive forces of the colloid 
probes with the lactose and budesonide substrates were measured by recording the deflection of 
the AFM cantilever as a function of the substrate displacement (z) by applying Hooke’s Law (F = -
kz). Individual force curves (n = 1024) were collected over a 10 µm x 10 µm area using the force 
volume mode at a scan rate of 4 Hz and a compressive load of 40 nN. Parameters were kept 
constant over the study. Quantification of the nominal spring constant of each cantilever was 
performed using a dynamic method of thermal noise analysis [27]. 
 
With the vast array of data generated during force volume measurements, custom-built software 
was used to extract data.  These collected force data were analysed to ensure normal distribution, 
indicating uniform contact between the drug probe and excipient substrate. Arithmetic mean and 
standard deviation were obtained from force data and used to produce the CAB plot. 
 
Powder bulk properties and flow and fluidisation characteristics  
 
Bulk and tapped densities (ρB and ρT, respectively) were measured using the FT4 powder 
rheometer (Freeman Technology, Tewkesbury, UK). For bulk density measurements, a 25 mm 
diameter, 20 ml volume split measurement vessel was placed on the measurement table of the 
instrument and the weight of the vessel tared. The vessel was then filled with the powder under 
investigation. A conditioning cycle was run to remove the influence of the filling procedure on 
powder packing. For measuring the bulk density, the measurement vessel was split and the split 
powder mass recorded. For tapped density measurements, the vessel was placed on a jolting 
volumeter (J. Engelsmann, Ludwigshafen, Germany) and 250 taps were applied. The vessel was 
then transferred back to the FT4 and the split powder mass recorded. All the measurements were 
performed in triplicate. The Hausner ratio (HR) that is a measure of the flow properties of powders 
with a value <1.25 indicating a free flowing powder and >1.25 indicating a poor flowing powder 
[28], was calculated according to Equation 1: 
 
   
  
  
           (1) 
 
The FT4 powder rheometer can be used for characterising flow properties of powders under 
different conditions to simulate the behaviour of powders while they are exposed to different 
environments during processing and usage. The normalised basic flow energy (BFENorm) is a 
general descriptor of powder flow properties and characterises the resistance of one gram of a 
chosen powder to flow under a constant speed with cohesive powders exhibiting low BFENorm [29]. 
The flow rate index (FRI) measurement on the other hand is a dimensionless parameter describing 
how different powders react to changes in the rate at which an impeller blade is traversed in a 
helical path. It has been shown that more cohesive powders appear to be more sensitive to such 
changes and therefore have higher FRI [29]. Specific energy (SE) is a parameter based on the 
force and torque measured in the rheometer during upward blade motion. The value of SE 
describes the flow properties of the powders in a stress free state at near zero consolidation due to 
the lack of a downward loading force by the blade [29]. The BFENorm, FRI and SE were measured 
during the same test procedure using a purpose-built measurement program. For these 
measurements, the powder was loaded in the 25mm bore diameter, 20 ml volume split vessel. At 
first, a downward conditioning cycle was run at a tip speed of -40 mm/s and a helical angle of 5° to 
remove the packing history of the powder. This was followed by an upward conditioning cycle at a 
tip speed of 40 mm/s and a helical angle of 5°. After conditioning, the measurement cell was split 
and the split mass recorded. Consecutive cycles of conditioning and BFE measurements were 
repeated seven times at a tip speed of -100 mm/s and helical angle of -5° to assess the stability of 
the powder under agitation. If the powder was observed to be stable, the BFE measured during the 
7th measurement cycle was divided by the split mass to calculate the BFENorm. SE was defined as 
the energy required to lift the blade out of the powder bed and was also measured during the 7th 
measurement cycle. To measure the FRI, four additional measurement cycles at tip speeds -100, -
70, -40 and -10 mm/s were run with an unaltered conditioning cycle between each of them. The 
FRI was calculated as the ratio of the flow energy measured at a tip speed of -10mm/s over the 
flow energy measured at a tip speed of -100 mm/s. 
 
The normalised fluidisation energy (FENorm) is defined as the energy required to keep the impeller 
blade moving through one gram of fluidised powder bed at a constant speed. The lower the value, 
the more easily the powder can be fluidised. Dynamic flow index (DFI) describes the reactivity of 
the powder to an air flow through the powder bed. The higher the value of DFI, the more the 
powder structure is affected by the fluidising gas flowing through the powder bulk. The FENorm and 
DFI were measured during the same measurement program. Powders were loaded into a 25mm 
bore diameter, 20ml volume split vessel. An initial conditioning cycle was repeated 8 times at a tip 
speed of -60 mm/s downward and 60 mm/s upward and helical angles of 5° and -5°, respectively, 
to remove the packing history of the powder. After the initial conditioning, the measurement cell 
was split. A cycle of conditioning and measuring was then repeated at different air velocities, 
controlled by an aeration control unit (ACU) of an FT4. The air velocity was adjusted such that, 
during the conditioning cycle, the air velocity was equal to the air velocity of the following 
measurement. The measurement cycles at the different air velocities were performed at a tip 
speed of -100 mm/s and a helical angle of -5° followed by an upward motion at a tip speed of 
60mm/s and a helical angle of 10°. The FENorm was calculated by dividing the fluidisation energy at 
the point where the powder became fully fluidised (no further decrease in flow energy upon 
increasing fluidising gas velocity) with the split mass of the powder bed. The DFI was calculated as 
the ratio between the flow energy at fluidising gas velocity of 0 mm/s by the flow energy at the 
minimum fluidisation velocity.   
Preparation and in vitro testing of budesonide DPI formulations  
 
Carrier based DPI formulations of micronised budesonide at 0.8 %w/w concentration with the 
different lactose pre-blends were prepared using a Turbula mixer at 46 rpm in 40 g quantities in the 
same blending vessel that was used for the preparation of the lactose pre-blends. Briefly, lactose 
blends were all passed through an 850µm aperture sieve to break any large agglomerates which 
may have formed during storage. A quarter of the mass of the lactose required was transferred to 
the blending vessel and the drug was sandwiched with another quarter the lactose pre-blend. This 
was blended for 10 minutes. The remaining half of the lactose was then added and blended for a 
further 45 minutes. After blending, formulations were passed through a 250 µm sieve and stored at 
20 ± 2°C and 44% RH for at least a week before the content uniformity of the blends was assayed.  
 
Content uniformity was analysed by taking ten random 12.5mg aliquots from each formulation. The 
drug content was assayed using high performance liquid chromatography (HPLC). The acceptance 
criteria for blend content uniformity were set according to USP<905> [30]. Formulations were 
subsequently hand-filled into size 3 Quali-V hydroxypropylmethylcellulose (HPMC) capsules 
(Qualicaps, Madrid, Spain) with a fill weight of 12.5 mg. 
 
In vitro performance of the formulations was assessed using a Next Generation Impactor (NGI) 
equipped with a pre-separator (Copley Scientific, Nottingham, UK). A Cyclohaler DPI device (Teva 
Pharmaceuticals, The Netherlands) was used at a flow rate of 90 litres per minute with 4L of air 
being drawn through the device. All impactor stage plates and the pre-separator were pre-coated 
with silicone oil and 15 ml of mobile phase was placed in the collection cup of the pre-separator 
before two capsules were aerosolised into the impactor. The drug deposited in the different stages 
of the impactor was assessed by dissolving the particles collected in mobile phase and analysing 
the drug content by HPLC. The fine particle fraction of emitted dose (FPFED) and mean mass 
aerodynamic diameter (MMAD) were determined by interpolation based on the mass of particles 
finer than 5 µm collected in the impactor, determined by regression analysis. The proportion of 
drug deposited in the pre-separator (PS of RD) was used as an indicator of the efficiency of drug 
detachment from the large lactose crystals [31]. 
 
High performance liquid chromatography (HPLC) drug analysis 
 
The samples were dissolved in a mobile phase that consisted of 20% water, 35% acetonitrile and 
45% methanol. The mobile phase was pumped through the HPLC system at a flow rate of 1.5 
ml/min using a PU-980 pump (Jasco, Tokyo, Japan). 100 µl of the samples were injected into the 
system using an AS-950 autosampler (Jasco, Tokyo, Japan). The 250 mm long Hypersil-ODS 
column with an inner diameter of 4.6mm and packing material particle size of 5 µm (Thermo 
Scientific, Loughborough, UK) was held at 40°C using a CO-965 column oven (Jasco, Tokyo, 
Japan). The eluted drug was detected using a UV-975 detector (Jasco, Tokyo, Japan) at a 
wavelength of 244 nm for budesonide. The retention time for budesonide was 3.75 min. 
 
 
Statistical analysis 
 
Linear correlations between the physical properties of the lactose carriers and the DPI 
performance of the formulations were established using Minitab v.15 statistical analysis package 
(Minitab Ltd, Coventry, UK). The strength of the linear correlation between the lactose properties 
and the DPI performance attributes was evaluated by the value of r (-1<r<1), with perfect 
correlation producing a value of 1 and the sign denoting the direction of the correlation. 
 
Artificial neural network analysis of the dataset 
 
The hierarchy, design and theoretical basis of ANNs can be found elsewhere [32]. The general 
structure of ANN has one input layer, many hidden layers and one output layer. Each layer 
incorporates many units corresponding to “neurons”, which are fully interconnected with links 
corresponding to synapses [32]. The strength of connections between two units are called 
“weights”. In each hidden layer and output layer the processing unit sums the input from the 
previous layer and then applies a sigmoidal function to compute its output to the following layer 
according to the following equations: 
 
   ∑                (2) 
 
 (  )    {           }          (3) 
 
where     is the weight of the connection between unit q in the current layer to unit p in the 
previous layer, and    is the output value from the previous layer [33]. The  (  ) is conducted to 
the following layer as an output value. Alpha is a parameter relating to the shape of the sigmoidal 
function, which is strengthened with an increase in alpha [18]. ANN learns an approximate non-
linear relationship by a procedure called “training”, which involves varying weight values. Training 
is defined as a search process for the optimised set of weight values, which can minimise the 
squared error between the estimation and experimental data of units in the output layer [18]. 
Training is an iterative process that may lead to under and over-estimation of the predicted output. 
This however, is avoided through the application of a backpropagation algorithm in combination 
with either the backsweep or recursive algorithms. The backpropagation algorithm consists of a 
forward propagation through a neural network, a backward propagation, and a weight update for 
each training step [33]. This processing helps to reduce the number of iterations and improves 
prediction from the neural design. Optimisation and validity of the study is not necessarily 
determined by the number of samples, but by the plurality of the study design that incorporates 
many units in each layer of the neural network. 
 
ANN analysis of data was performed using Alyuda Neurointelligence software (Alyuda 
Neurointelligence, California, USA). The input data were pre-processed so that the range of input 
values were within the range of [-1…1] and output values within the range of [0…1]. The dataset 
was partitioned to training, test and validation sets, with 27 records (70%) being used for the 
training set and 6 (15%) for both the validation and test sets. A batch back-propagation training 
algorithm was used for the network training. The network architecture was selected manually as 
12-4-1 for fine particle fraction of the emitted dose and 12-5-1 for mean mass aerodynamic 
diameter and pre-separator deposition. The logistic transfer function [32] and sum of squares error 
function [34] were used for determining the firing intensity of a neuron and the error between the 
actual and predicted output, respectively. For all the networks, a momentum of 0.9 was used. The 
learning rate was set to 0.1 for the ANN modelling of the fine particle fraction of the emitted dose 
and pre-separator deposition, and 0.25 for the ANN network modelling of the mean mass 
aerodynamic diameter. In all cases, network training was stopped by error change when the mean 
square error of the network or the dataset error over 10 training cycles changed by less than 
0.0000001.  
 
 
 
  
Results and Discussion 
 
Physicochemical characterisation of the raw materials 
 
The particle size distribution (PSD) of the micronised budesonide is shown in Figure 1. The d10, d50 
and d90 of the budesonide batch were 0.80, 2.08 and 4.4µm, respectively. The mean force of 
cohesion (drug probe interaction with drug crystal) of five probes of the micronised budesonide 
were plotted against the corresponding mean force of adhesion (drug probe interaction with lactose 
crystal) to form the CAB plot, as shown by Figure 2. Linear regression analysis through the origin 
of the CAB data showed a linear fit with a regression coefficient of 99.8%. The gradient of each 
plot was equated to determine the CAB ratio of the micronised budesonide. The CAB value of the 
micronised budesonide 0.62 ± 0.02 was similar to previously reported CAB measurements of 
commercially supplied micronised budesonide with lactose monohydrate [35,36]. These data 
suggest that for an equivalent force of cohesion the adhesion of the micronised budesonide to 
lactose is approximately 1.61 times greater than its drug-drug interaction and is therefore a highly 
suitable candidate molecule for investigating the role of fines for an adhesive drug.  
 
The particle size distributions of the coarse lactose (LH100, LH206 and SV010), micronised 
lactose fines (LH300) and milled fine lactose grades (LH230, LH210 and Sorbolac 400) are shown 
in Figure 3 and their characteristic properties summarised in Table II. The rank order of the level of 
intrinsic lactose fines (%≤4.5µm) of the coarse carriers are LH206 > SV010 > LH100. The 
corresponding order for the fine lactose fractions is LH300 > LH230 > LH210 ~ Sorbolac 400.  
Despite LH210 and Sorbolac 400 having similar proportions of %<4.5 µm, in terms of d10, d50 and 
d90 and particle size distributions (Figure 3) LH230 and Sorbolac 400 are similar to each other. 
 
Physical and bulk powder characterisation of lactose pre-blends 
 
The fine lactose particle content of the pre-blends from particle size measurements are 
summarised in Table III. These data indicate that the proportion of lactose fines below 4.5 µm 
ranged between 1.3% and 23% and the proportion of particles finer than 15 µm and 30 µm ranged 
from 2.5 to 40% and 3.8 to 43%, respectively. These differences in the fines content within the pre-
blends were also reflected by variability in the d10 values of the carrier blends, which ranged 
between 1.7 and 50 µm. 
 
The corresponding bulk and tapped densities and powder flow and fluidisation properties of the 
carrier pre-blends are summarised in Table IV. The Hausner ratio for the pre-blends varied 
between 1.14 and 1.54. Carriers that exhibited the lowest Hausner ratios corresponded to the pre-
blends that contained no added lactose fines. The addition of lactose fines significantly increased 
the Hausner ratio and thereby reduced the flowability of the pre-blends. 
 
These findings were confirmed by powder rheological measurements of the lactose pre-blends, 
tabulated in Table IV. A range of rheological properties were analysed including the basic flow 
energy (BFEnorm) and fluidisation energy (FEnorm), which were both normalised to the powder mass 
tested, the dynamic flow index (DFI), flow rate index (FRI) and specific energy (SE). In general, as 
powders became more cohesive the FENorm and FRI increase while the BFEnorm and DFI values 
decrease [29]. Therefore, the flow and fluidisation parameters measured for the carriers suggested 
that increasing the amount of lactose fines reduced the flowability and increased the energy 
required to fluidise the pre-blends. Unlike the Hausner ratio measurements, which were relatively 
insensitive to the type of fines (micronised vs. milled) present in the pre-blend, powder rheological 
data suggested that at high concentration micronised lactose fines had the most significant effect 
on reducing flow and increasing the cohesive properties of the pre-blends. In summary, the 
parameters describing the flow and fluidisation properties of the lactose pre-blends indicated that 
increasing fines content increased the cohesive strength of the lactose pre-blend. This is in an 
agreement with reported studies of Shur et al., who suggested that upon addition of lactose fines 
an increase in the cohesive strength is observed, which in turn may lead to greater 
deagglomeration efficiency of the micronised drug and thereby improving performance [37]. 
 
In vitro aerodynamic particle size distribution (APSD) testing of budesonide DPI 
formulations 
 
The results of the in vitro aerodynamic particle size distribution (APSD) measurements of the 
budesonide formulations prepared with all 39 different pre-blends, aerosolised from a Cyclohaler at 
90 l/min, are summarised in Table V. The results were recorded as fine particle fraction of emitted 
dose (FPFED), mean mass aerodynamic diameter (MMAD) and the proportion of drug recovered 
from the pre-separator (PS of RD).  
 
The fine particle delivery (FPFED) of budesonide (Table V) was significantly affected by the type 
and level of lactose fines added to the three different coarse grades of lactose (LH100, LH206 and 
SV010, see Table I), and ranged between 20.8% and 46.9%.  For the capsule-based Cyclohaler 
device, the addition of the micronised LH300 fines to the coarse carriers had the most significant 
influence on increasing the fine particle fraction, and concomitantly reduced the amount of drug 
retained on the coarse lactose recovered from the pre-separator.  However, despite increasing the 
cohesive strength of the lactose carrier pre-blends, the addition of the milled fines (LH230, LH210 
and Sorbolac 400) did not lead to as significant an improvement in the DPI performance as the 
addition of micronised LH300 lactose fines. These data suggest that the increasing the cohesive 
strength of the formulation may not be the dominant attribute in improving performance upon the 
addition of Geldart group C fines [38].  
 
For all formulations, the MMAD of the drug increased with increasing levels of milled and 
micronised fines, ranging from 2.58 µm to 3.51 µm. These data suggest that agglomeration and 
co-deposition of the API with lactose fines on the impactor stages may have occurred.  
 
Linear correlations between the physical properties of the carrier and the in vitro 
performance of the formulations 
 
Linear correlations have been previously observed between different parameters relating to lactose 
properties and DPI performance on relatively small datasets [9,11,39]. Thus, the initial approach 
utilised in understanding the critical attributes of lactose fines and how they may influence the bulk 
powder properties and govern deagglomeration and drug detachment efficiency of DPI 
formulations, was to conduct statistical analysis for linear correlations for the current dataset. 
 
The correlation coefficients (r) from these analyses are summarised in Table VI and shown in 
Figure 4. These data (Table VI and Figure 4A) indicate that in predicting the fine particle fraction of 
emitted dose (FPFED), the percentage of fine particle lactose %≤4.5 µm in the carrier produced the 
best linear correlation with an r = 0.861. These data are in good agreement with studies published 
by various other researchers where the proportion of lactose fines was shown to correlate directly 
with DPI performance [11,12,14]. It is also notable that in the current study the r value between 
different particle size parameters decreased from 0.861 to 0.740 and 0.638 when the fines fraction 
percentages were measured as %≤4.5 µm, %≤15 µm and %≤30 µm, respectively. These data are 
also in an agreement with a previous study where the finer fractions of lactose were seen to 
produce a better correlation with DPI performance [40].   
 
One of the theories for explaining the improvement in DPI performance with fines is that the 
fluidisation properties of the bulk powder change due to an increase in cohesive strength upon the 
addition of Geldart type C [38] fine powders [37]. To test this theory, the correlation coefficients for 
linear correlations between the cohesive properties of the carriers (Table IV) and FPFED are shown 
in Table VI. The FPFED had positive correlations of 0.748, 0.649 and 0.578 against FENorm, Hausner 
ratio and FRI, respectively. The relationship between the BFENorm and FPFED was characterised by 
a negative correlation of -0.664. These results suggest that, indeed, the more cohesive the carrier 
blend, the higher the DPI formulation performance. However, because the r values are relatively 
low, the linear models based on flow and fluidisation properties of the carrier appeared not to be 
able to differentiate variations in the different grades of lactose fines with the FPFED. 
Figure 4A and Table VI indicate that linear correlation analysis of the MMAD as a function of the 
carrier properties produced the highest degree of correlation for the proportion of fines %≤15 µm 
and %≤30 µm with an r = 0.907 and r = 0.924, respectively. These data further indicate the 
complex nature of these formulations, where the interaction of the drug with coarser fines leads to 
a significant increase in aerodynamic diameter of the aerosolised drug, while having a minimal 
influence on increasing fine particle delivery. It has been previously suggested that these fines may 
be of sufficient size to act as secondary carriers [40].  
 
The strongest correlation between the physical properties of the lactose blends and the pre-
separator deposition was with FENorm with an r = -0.891, together with %<15 µm and %<4.5 µm 
with a coefficient of determination of -0.885 and 0.882, respectively (Figure 4C and Table VI). 
These data indicate that the fluidisation properties of the lactose carrier alongside the fine particle 
content may be important in determining the extent of drug detachment from the surface of the 
large carrier crystals. 
 
It is noteworthy, as highlighted in Figure 4, that linear correlation analysis of the comparatively 
large dataset appeared to produce relatively high correlation coefficients for all the different 
parameters utilised for describing the properties of the lactose pre-blends. It is, therefore, not 
surprising that when smaller datasets are investigated, good linear correlations are frequently 
reported between carrier properties and DPI performance.     
 
Artificial neural network analysis of the datasets 
 
In the current study, the ANN was used as a tool for predictively understanding the complex 
behaviour of how lactose fines govern DPI performance of an adhesive drug in a Cyclohaler. By 
inspecting the relative importance of the different input parameters of the lactose powders in the 
trained networks, the importance of each of the parameters could be measured against the 
different performance indicating attributes associated with DPI performance. These data are 
summarised in Table VII.  
 
The relative importance of the different input parameters in the network modelling FPFED, listed in 
Table VII, is shown in Figure 5A. The proportion of fines below %<4.5 µm was the most important 
parameter, with over 57% of the connection weights derived from this parameter. This is in an 
agreement with the outcome of linear statistical model based on the highest r values. The 
rheological FRI measurement was also shown to correlate with the FPFED, but to a considerably 
lower degree of importance.  
 
In modelling the MMAD, the proportion of fines %<15 µm was by far the most important parameter 
with 76% of the connection weights in the ANN being derived from the single parameter. These 
data are shown in Table VII and illustrated in Figure 5B. This indicates, that although the proportion 
of fines %<4.5 µm was the most important parameter in determining the DPI performance as 
defined by FPFED, coarser fines may play a role in determining the extent of deagglomeration of 
the drug.  
 
As shown in Table VII and Figure 5C, the proportion of lactose fine particles %<4.5 µm was the 
most important parameter in relation to drug deposition in the pre-separator with a 46% connection 
weight. These data suggested that an increased percentage in the proportion of fine particle 
lactose particles %<4.5 µm with respect to the coarser size fractions of the fines led to the 
decrease in the drug deposition in the pre-separator. This is supported by the fact that the second 
most important parameter was the 10th percentile of the particle size distribution (d10).  
 
From the ANN data (Figure 5 and Table VII), a number of different physical and bulk powder 
parameters characterised for the lactose pre-blends appeared to have a relatively small influence 
on DPI performance attributes. These were mainly the flow related measurements of specific 
energy, tapped density and Hausner ratio.  
 
The results also suggested that there might be a direct correlation between efficiency of drug 
detachment from the carrier and fine particle fraction delivery. The deagglomeration efficiency of 
the drug from the carrier, as measured by the proportion of drug collected in the pre-separator as a 
function of the recovered dose, was mainly affected by the proportion of the finer (%<4.5 µm) 
lactose fines, as was also the FPFED. These findings suggest that a significant reduction in pre-
separator deposition is achieved with greater concentrations of finer (%<4.5 µm) lactose. An 
increasing concentration of %<15 µm lactose fines with respect to the concentration of fines 
(%<4.5 µm) may lead to a greater drug retention of the drug on the lactose at the pre-separator, 
which supports the theory that the coarser fraction of milled lactose fines may be acting as 
secondary carriers [40]. 
 
The addition of these coarser fines was also shown to affect the aerodynamic particle size 
distribution of the API, as measured by the MMAD. For the ANN model, the proportion of fines 
%<15 µm appeared to influence the MMAD of the budesonide. These models suggest that an 
increase in the relative amount of the lactose fines between 4.5 µm and 15 µm and possibly up to 
30µm leads to the shift in the aerodynamic diameter of the measurements of the API, with greater 
deposition of the drug on the upper stage of the impactor.  
 
These data suggest that for a population of data, the ANN methodology may help in identifying key 
CMAs of lactose that affect drug product quality. In the context of QbD, this may allow greater 
understanding of material properties that may affect drug product behaviour and can therefore be 
utilised to control and continually improve the drug product.  
  
Conclusions 
 
The performance of DPI formulations appears to be governed by a multitude of excipient properties 
that often cannot be changed in a controlled manner or independently from one another. In this 
study, ANN analysis of the structure-function data was used together with linear regression to 
obtain a more complete understanding of the cause and effect relationship of the influence of fine 
lactose on the DPI performance of an adhesive drug in a capsule-based inhaler device. Linear 
regression of the datasets suggested a number of physical and bulk related properties might 
influence the key in vitro performance parameters. ANN analysis suggested that the only critical 
parameters required in describing the in vitro deposition patterns were the relative measurements 
of the concentration of lactose fines %<4.5 µm and %<15 µm. For the ANN model, the 
deagglomeration efficiency as measured by fine particle delivery performance was pre-dominantly 
governed by the proportion of fine lactose particles %<4.5 µm and the proportion of fine lactose 
particles %<15 µm appeared to govern the increase in the MMAD of the drug. ANN analysis 
suggested that the most dominant property in decreasing the amount of drug retained in the pre-
separator was the percentage of fines below %<4.5 µm. 
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Table I Summary of the coarse and fine lactose components used for preparing the carrier pre-
blends for the current study and the process history and the weight-to-weight % (wt-%) 
concentrations of the fines present in the different pre-blends 
Carrier ID 
Coarse 
fraction 
Type of 
Fines 
Fines 
Wt-% 
fines 
1 LH100 - - 0 
2 LH100 Micronised LH300 2.5 
3 LH100 Micronised LH300 5 
4 LH100 Micronised LH300 10 
5 LH100 Micronised LH300 20 
6 LH100 Milled LH230 2.5 
7 LH100 Milled LH230 5 
8 LH100 Milled LH230 10 
9 LH100 Milled LH230 20 
10 LH100 Milled LH210 2.5 
11 LH100 Milled LH210 5 
12 LH100 Milled LH210 10 
13 LH100 Milled LH210 20 
14 LH100 Milled Sorbolac 400 2.5 
15 LH100 Milled Sorbolac 400 5 
16 LH100 Milled Sorbolac 400 10 
17 LH100 Milled Sorbolac 400 20 
18 LH206 - - 0 
19 LH206 Micronised LH300 2.5 
20 LH206 Micronised LH300 5 
21 LH206 Micronised LH300 10 
22 LH206 Micronised LH300 20 
23 LH206 Milled LH230 2.5 
24 LH206 Milled LH230 5 
25 LH206 Milled LH230 10 
26 LH206 Milled LH230 20 
27 LH206 Milled LH210 2.5 
28 LH206 Milled LH210 5 
29 LH206 Milled LH210 10 
30 LH206 Milled LH210 20 
31 SV010 - - 0 
32 SV010 Micronised LH300 2.5 
33 SV010 Micronised LH300 5 
34 SV010 Micronised LH300 10 
35 SV010 Micronised LH300 20 
36 SV010 Milled LH210 2.5 
37 SV010 Milled LH210 5 
38 SV010 Milled LH210 10 
39 SV010 Milled LH210 20 
 
 
 
 
 
 
Table II 10th, 50th and 90th percentiles (d10, d50 and d90 respectively) of particle size distributions 
coarse lactose carriers (LH100, LH206 and SV010) and the lactose fines (LH300, LH230, LH210 
and Sorbolac 400) used in the study dispersed dry at 2 bar disperser pressure. The results are an 
average from five repeated measurements. 
 
 
d10 
(µm) 
d50 
(µm) 
d90 
(µm) 
%<4.5 
LH100 44.3 103.37 159.62 1.29 
LH206 49.78 93.05 142.21 2.44 
SV010 49.61 108.78 166.78 1.55 
LH300 0.84 2.41 7.76 77.13 
LH230 1.31 8.05 21.97 35.68 
LH210 1.64 14.3 39.45 23.84 
Sorbolac 400 1.79 9.28 22.12 23.85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table III Summary of particle size of the carrier pre-blends in terms of proportion of fines below 4.5, 
15 and 30 µm and the 10th percentile of density distribution (d10) measured dispersed dry at 3 bar 
disperser pressure. The values shown are averages from five repeated measurements. 
Carrier  
ID 
Fines 
<4.5 µm 
(%) 
<15 µm 
(%) 
<30 µm 
(%) 
d10 
(µm) 
1 0% 1.29 3.02 6.24 44.3 
2 2.5% Micronised 4.88 8.25 11.48 23.44 
3 5% Micronised 9.34 13.94 17.03 5.22 
4 10% Micronised 17.43 24.52 26.97 2.08 
5 20% Micronised 23.04 40.24 42.75 1.73 
6 2.5% Milled 2.76 6.70 10.95 26.41 
7 5% Milled 4.32 10.15 15.13 14.7 
8 10% Milled 7.23 16.78 23.23 7.33 
9 20% Milled 12.47 28.93 38.15 3.26 
10 2.5% Milled 1.98 5.14 9.56 31.53 
11 5% Milled 2.62 6.78 12.27 23.63 
12 10% Milled 4.08 10.44 17.89 14.25 
13 20% Milled 6.02 15.91 26.79 8.72 
14 2.5% Milled 2.37 6.23 10.05 29.77 
15 5% Milled 3.32 9.20 13.81 17.01 
16 10% Milled 5.88 15.60 21.72 8.68 
17 20% Milled 10.20 27.62 36.7 4.39 
18 0% 2.44 2.54 3.81 49.78 
19 2.5% Micronised 6.13 8.11 9.27 34.3 
20 5% Micronised 10.42 13.76 14.8 4.11 
21 10% Micronised 18.16 24.42 25.24 1.95 
22 20% Micronised 22.43 39.53 40.6 1.8 
23 2.5% Milled 3.69 6.49 8.69 36.76 
24 5% Milled 5.29 9.99 13.01 15.08 
25 10% Milled 8.04 16.30 20.79 6.74 
26 20% Milled 12.40 27.77 35.18 3.28 
27 2.5% Milled 3.45 5.50 7.91 38.48 
28 5% Milled 3.66 6.74 10.21 29.09 
29 10% Milled 5.05 10.51 16.23 13.97 
30 20% Milled 7.01 16.79 26.57 7.67 
31 0% 1.55 3.03 5.19 49.61 
32 2.5% Micronised 3.17 6.23 8.07 40.48 
33 5% Micronised 6.51 11.75 13.57 9.18 
34 10% Micronised 12.08 21.08 22.61 3.49 
35 20% Micronised 22.47 38.05 39.33 1.74 
36 2.5% Milled 2.01 4.41 7.46 40.97 
37 5% Milled 2.57 6.03 10.16 29.42 
38 10% Milled 3.63 9.29 15.53 16.54 
39 20% Milled 6.53 16.38 26.27 8.13 
 
  
Table IV Flow and fluidisation properties of the carrier pre-blends in terms of bulk and tapped 
densities, Hausner ratio, Basic flow energy (BFENorm), dynamic flow index (DFI), flow rate index 
(FRI), normalised fluidisation energy (FENorm) and specific energy (SE). The values shown are 
averages from three repeated measurements 
 
Carrier 
ID 
Fines 
Bulk 
density 
(g/ml) 
Tapped 
density 
(g/ml) 
Hausner 
ratio 
BFENorm
 
(mJ/g) 
DFI FRI 
FENorm
 
(mJ/g) 
SE 
(mJ/g) 
1 0% 0.747 0.855 1.159 25.12 37.37 1.02 0.70 6.02 
2 2.5% Micronised 0.727 0.854 1.224 22.06 27.90 1.10 0.84 5.84 
3 5% Micronised 0.699 0.847 1.250 20.34 16.61 1.19 1.23 6.06 
4 10% Micronised 0.667 0.860 1.380 15.68 10.87 1.52 1.44 6.25 
5 20% Micronised 0.681 0.869 1.464 9.93 5.69 2.41 1.75 6.27 
6 2.5% Milled 0.709 0.865 1.216 21.65 24.07 1.06 0.95 6.14 
7 5% Milled 0.676 0.866 1.252 19.37 18.49 1.09 1.12 6.12 
8 10% Milled 0.645 0.880 1.358 16.07 10.74 1.29 1.54 6.10 
9 20% Milled 0.560 0.867 1.474 10.52 6.15 1.81 1.93 5.66 
10 2.5% Milled 0.731 0.863 1.183 23.48 31.39 1.03 0.78 5.96 
11 5% Milled 0.711 0.872 1.221 21.11 21.14 1.06 1.00 6.00 
12 10% Milled 0.699 0.881 1.264 19.54 19.56 1.14 1.04 6.08 
13 20% Milled 0.621 0.882 1.369 13.24 9.21 1.41 1.60 5.85 
14 2.5% Milled 0.703 0.859 1.223 21.26 24.92 1.08 1.01 5.87 
15 5% Milled 0.695 0.871 1.254 20.23 18.91 1.13 1.17 6.13 
16 10% Milled 0.669 0.883 1.319 16.95 13.68 1.25 1.33 6.26 
17 20% Milled 0.625 0.893 1.428 11.81 8.52 1.88 1.44 6.26 
18 0% 0.744 0.861 1.135 22.67 30.23 1.08 0.82 5.58 
19 2.5% Micronised 0.708 0.854 1.206 19.85 17.55 1.10 1.14 5.94 
20 5% Micronised 0.668 0.857 1.284 17.60 11.74 1.16 1.53 6.09 
21 10% Micronised 0.613 0.856 1.396 15.65 8.02 1.42 1.93 6.29 
22 20% Micronised 0.604 0.875 1.449 9.96 4.96 2.27 1.88 6.21 
23 2.5% Milled 0.725 0.881 1.214 21.00 23.78 1.08 0.93 6.20 
24 5% Milled 0.692 0.874 1.264 19.71 15.90 1.09 1.41 6.59 
25 10% Milled 0.663 0.877 1.324 15.75 10.55 1.27 1.56 6.29 
26 20% Milled 0.575 0.883 1.537 11.48 6.06 1.66 1.89 5.96 
27 2.5% Milled 0.733 0.869 1.186 21.47 28.66 1.05 0.81 5.68 
28 5% Milled 0.720 0.873 1.212 19.68 21.50 1.09 1.00 5.70 
29 10% Milled 0.683 0.879 1.288 17.36 15.27 1.15 1.22 5.99 
30 20% Milled 0.635 0.885 1.395 13.34 9.70 1.39 1.49 6.01 
31 0% 0.729 0.845 1.158 26.03 51.02 1.11 0.57 5.74 
32 2.5% Micronised 0.729 0.858 1.177 23.60 41.61 1.10 0.57 5.72 
33 5% Micronised 0.703 0.849 1.209 20.74 17.52 1.15 1.14 5.99 
34 10% Micronised 0.636 0.855 1.344 9.55 9.55 1.32 1.91 6.17 
35 20% Micronised 0.599 0.861 1.438 10.18 6.39 2.45 1.57 6.19 
36 2.5% Milled 0.741 0.858 1.158 25.79 34.31 1.09 0.80 5.80 
37 5% Milled 0.725 0.865 1.193 22.83 31.65 1.10 0.78 5.76 
38 10% Milled 0.687 0.862 1.255 18.95 24.34 1.15 1.03 5.90 
39 20% Milled 0.645 0.887 1.375 15.35 10.63 1.43 1.52 6.21 
 
  
Table V Summary of in vitro performance of the formulations prepared with the lactose pre-blends 
as the carrier in terms of fine particle fraction of emitted dose (FPFED), mean mass aerodynamic 
diameter (MMAD) and the proportion of total recovered budesonide that was deposited in the pre-
separator (PS of RD). The results shown are averages from three repeated in vitro assessments. 
 
Carrier 
ID 
Fines 
FPF of ED 
(%) 
MMAD 
(µm) 
PS of RD 
(%) 
1 0% 24.10 2.58 38.23 
2 2.5% Micronised 26.56 2.94 31.00 
3 5% Micronised 35.78 3.04 21.17 
4 10% Micronised 46.94 3.09 13.37 
5 20% Micronised 39.74 3.36 12.74 
6 2.5% Milled 23.85 2.78 35.15 
7 5% Milled 25.32 3.00 31.68 
8 10% Milled 28.21 3.26 21.63 
9 20% Milled 35.95 3.25 15.42 
10 2.5% Milled 23.13 2.75 37.09 
11 5% Milled 24.14 2.85 33.94 
12 10% Milled 27.38 3.00 25.87 
13 20% Milled 26.63 3.14 23.97 
14 2.5% Milled 21.03 2.86 42.90 
15 5% Milled 22.08 2.92 37.80 
16 10% Milled 27.19 3.04 28.27 
17 20% Milled 26.90 3.51 20.47 
18 0% 24.56 2.62 39.31 
19 2.5% Micronised 32.49 2.81 27.04 
20 5% Micronised 36.09 2.92 21.73 
21 10% Micronised 44.71 3.19 13.63 
22 20% Micronised 36.73 3.48 14.53 
23 2.5% Milled 25.50 2.78 32.30 
24 5% Milled 26.75 2.89 28.46 
25 10% Milled 28.69 3.15 23.31 
26 20% Milled 32.89 3.34 18.56 
27 2.5% Milled 23.28 2.70 38.94 
28 5% Milled 25.11 2.79 34.34 
29 10% Milled 24.33 2.88 30.23 
30 20% Milled 30.41 3.01 22.93 
31 0% 20.82 2.65 44.25 
32 2.5% Micronised 23.28 2.96 34.95 
33 5% Micronised 30.63 3.04 27.09 
34 10% Micronised 39.65 3.12 17.12 
35 20% Micronised 35.15 3.40 13.84 
36 2.5% Milled 22.26 2.77 41.25 
37 5% Milled 23.05 2.91 40.17 
38 10% Milled 24.42 3.02 36.12 
39 20% Milled 25.52 3.01 23.49 
 
 
 
 
 
Table VI Coefficient of correlation (r) for linear relationships between the different DPI performance 
measures and the properties of the lactose pre-blends used as the carriers in the formulations. The 
correlations are based on the average values reported in Tables IV, V and VI. 
 Correlation coefficient (r) 
 FPFED
1 MMAD2  PS of RD3 
<4.5 µm 0.861 0.793 -0.882 
<15 µm 0.740 0.907 -0.885 
<30 µm 0.638 0.924 -0.862 
d10 -0.687 -0.839 0.867 
Bulk density  -0.589 -0.839 0.805 
Tapped density  -0.147 0.368 -0.226 
Hausner ratio 0.649 0.889 -0.866 
BFENorm -0.664 -0.864 0.872 
DFI -0.673 -0.784 0.870 
FRI 0.578 0.825 -0.741 
FENorm  0.748 0.800 -0.891 
SE  0.413 0.431 -0.533 
1 Fine particle fraction of emitted dose (FPFED) 
2 Mean mass aerodynamic diameter (MMAD) 
3 Proportion of budesonide recovered from the pre-separator (PS of RD) 
 
Table VII The connection weights for the different input parameters in the neural networks 
describing DPI performance. The networks were based on the average values reported in Tables 
IV, V and VI. 
 Connection weights (%) 
 FPFED
1 MMAD2 PS of RD3 
%<4.5 56.94 2.50 45.76 
%<15 0.09 75.56 1.05 
%<30 1.24 0.45 5.27 
d10 3.64 4.82 19.17 
BFENorm 0.57 0.08 9.05 
Bulk density 6.78 1.99 7.78 
Tapped density 3.75 1.56 3.45 
Hausner ratio 4.91 4.45 0.43 
DFI 7.90 0.37 4.21 
FENorm 0.13 7.15 2.88 
FRI 13.65 0.18 0.03 
SE 0.41 0.88 0.92 
 
1 Fine particle fraction of emitted dose (FPFED) 
2 Mean mass aerodynamic diameter (MMAD) 
3 Proportion of budesonide recovered from the pre-separator (PS of RD) 
 
 
 
Legend to figures 
 
Figure 1. Particle size distribution of budesonide measured dispersed wet. The data represented is 
an average from five repeated measurements. 
 
Figure 2. Cohesive-adhesive balance (CAB) plot for the batch of budesonide. The dotted line 
represents Fcoh=Fadh and corresponds to CAB value of 1. 
 
Figure 3. Particle size distributions of lactoses measured dry dispersed at 2 bar disperser pressure. 
Black lines represent the coarse carriers (LH100, LH206 and SV010), light grey micronised lactose 
(LH300) and dark grey milled lactose grades (LH230, LH210 and Sorbolac 400). The data 
represents an average of five repeated measurements. 
 
Figure 4. Coefficients of correlation (r) for linear correlations between different parameters 
describing the properties of the lactose carriers and A) fine particle fraction of emitted dose B) 
mean mass aerodynamic diameter and C) pre-separator deposition of budesonide.  
 
Figure 5. The relative importance of the different input parameters (connection weights) in the 
neural network modelling the relationship between the parameters describing the properties of the 
lactose carrier and A) fine particle fraction of emitted dose B) mean mass aerodynamic diameter 
and C) pre-separator deposition of budesonide 
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